Robotic parts manufacturer Dobot receives USD 10 million for Series A
Founder: Liu Chaopei
Founded in: 2015
Financing status: RMB 70 million (USD 10 million) Series A financing in 2017
Robotic parts manufacturer Dobot on Thursday receives USD 10 million for its Series A round for the research and development of new robotic parts and marketing.
Dobot is a robotic parts manufacturer that mainly focuses on the development and upgrading of industrial robotic parts, and the development of extensive applications for robotic parts in China. Founded in 2015 in Shenzhen, it has now launched three products.
Dobot 1.0 is a robotic arm that has been used in some manufacturing industries and can be operated with high precision. It can be controlled by smartphones, computers, gesture and voice recognition.
Dobot Magician is the second generation robotic arm that integrates with 3D printing, laser engraving and some other areas. It also has 13 extension ports which can be further developed by customers based on their specific demands.
Dobot M1 is its latest mechanical arm with wide usage in some industries. Its easily used robotic arms can be combined with machines in the medical, catering, office, and education fields.
This Series A financing round was from Shenzhen Capital Group and Qianhai. This capital will be used in the research and development of new robotic parts, as well as expanding its business to the education industry.
Biotech company InventisBio receives USD 19 million for Series B
Founded in: 2015
Financing status: RMB 129 million (USD 19 million) Series B financing in 2017
Biotech company InventisBio on Thursday receives USD 19 million for its Series B round for the discovery and development of new medicine.
InventisBio is a biotech company that mainly produces drugs that target therapies for lung cancer, breast cancer and gout. It also actively develops some other drugs that integrate with other immuno-oncology targeted therapies for various cancer indications.
Founded in 2015 in Shanghai, it currently has operation centers in both China and the U.S. In addition, InventisBio has developed four drug candidates for cancers and gout therapeutic areas so far. Three of them are expected to enter phase 1 clinical trials in the U.S. and China this year.
Previously, the company received funding from Beautiful Mind Investment Management Ltd in 2015, Lilly Asia Venture and Sinopharm Capital in May 2016. This Series B financing round was led by OrbiMed Asia Partners, with Lilly Asia Ventures joining as an investor. InventisBio plans to use the fund for the discovery and development of new medicine, and aims to sell its drug and medical solutions all over the world.
（Top photo from 58pic.com）